# Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings

> **NCT00884390** · PHASE4 · TERMINATED · sponsor: **Pfizer** · enrollment: 208 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** moroctocog alfa (AF-CC) (ReFacto AF)
- **PROCEDURE:** Laboratory tests

## Key facts

- **NCT ID:** NCT00884390
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-05
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 208 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2014-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00884390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00884390, "Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings". Retrieved via AI Analytics 2026-08-19 from https://api.ai-analytics.org/clinical/NCT00884390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*